Pancreatic ductal adenocarcinoma: Current and evolving therapies
Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world. Due to the broad heterogeneity of genetic mutations and dense stromal environment, PDAC belongs to one of the most chemoresistant cancers. Most of...
| Main Authors: | , , |
|---|---|
| Format: | Journal Article |
| Published: |
MDPI AG
2017
|
| Online Access: | http://hdl.handle.net/20.500.11937/54405 |